Figure 4. Validating candidate compounds that selectively target CIN cells.

(A, B, C, D, E, F) Growth curves of control and Mad2^cKD RPE1 cells treated with 0.1 μM (A) and 0.01 μM (B) compound #1561, (C) 1 μM compound #2831, (D, E, F) 0.1 μM, 0.5 μM, and 1 μM 1,407, respectively. Data were obtained by sequential daily microscope images and analyzed by FIJI-PHANTAST. Each point is a minimum of three biological replicates, each of which contains three technical replicates. Plotted is log-scaled percentage confluency (cell coverage) over time. Error bars indicate SEM. P-values are calculated from paired, one-sided t tests of AUC corrected for cell line control. RPE1 DMSO and Mad2^cKD DMSO curves shared between (A) and (B), and between (C) and (F) and Fig S3C, and between (D) and (E). (G, H) IncuCyte growth curves of control and Mad2^cKD RPE1 cells treated with Src inhibitors SKI-1 (G) or compound #1407 (H, SKI606) for day 8–16. (I) IncuCyte growth curves for control- and reversine-treated RPE1 cells with and without conditional Src knockdown. All points include data for six technical replicates. Error bars refer to SEM, and P-values were calculated from two-sided t test of the AUC corrected for cell line controls. Data for DMSO control curves are shared between (G, H) and Fig 5G.